Report on extraordinary general meeting held in NeuroSearch A/S

Announcement                                                                    


Report on extraordinary general meeting held in NeuroSearch A/S                 

An extraordinary general meeting was held today in NeuroSearch A/S.             

Mr Thomas Hofman-Bang, President and CEO of NKT Holding A/S, was elected as a   
new member of the Board of Directors.                                           

The suggested amendment to article 5 of the Articles of Association regarding   
the Board of Directors' authorisation to increase the company's share capital   
was adopted by the general meeting with more than two-thirds majority but could 
not be finally adopted as less than half of the share capital was represented at
the general meeting.                                                            

An extraordinary general meeting will therefore be held on 21 December 2007 at  
10 am where the same amendment to the Articles of Association will be presented 
for final adoption.                                                             


Asger Aamund                                                                    
Chairman of the Board                                                           


Contact persons:

Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118

Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate 
Communications, telephone: +45 4460 8212 or +45 4017 5103 



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. Our core business covers the development of     
novel drugs, based on a broad and well-established drug discovery platform      
focusing on ion channels and CNS disorders. A substantial part of the Company's 
activities are partner financed through a broad alliance with GlaxoSmithKline   
(GSK) and collaborations with among others Abbott and Astellas. The drug        
pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in   
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase  
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in     
partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD   
(Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in             
schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder
and Parkinson's disease (Phase I) and ABT-107 as well as ABT-560 for the        
treatment of various CNS diseases - both (Phase I) in collaboration with Abbott 
as well as NSD-644 (Phase I) in collaboration with GSK. In addition, NeuroSearch
has a broad portfolio of preclinical drug candidates and holds equity interests 
in several biotech companies.